Evidence map›Paper›PMID 35820915›Full record

ArticleAlzheimer's research & therapy2022

Multidomain trials to prevent dementia: addressing methodological challenges.

Manuel Montero-Odasso, G Y Zou, Nellie Kamkar, Howard H Feldman, Sylvie Belleville, Howard Chertkow, Haakon B Nygaard, Surim Son, Mark Speechley

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Manuel Montero-OdassoSchulich School of Medicine and Dentistry, Department of Medicine and Division of Geriatric Medicine, The University of Western Ontario, London, ON, Canada. mmontero@uwo.ca.ORCID 0000-0002-5796-2361
G Y ZouDepartment of Epidemiology and Biostatistics, The University of Western Ontario, London, ON, Canada.
Nellie KamkarGait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, ON, Canada.
Howard H FeldmanDepartment of Neurosciences, Alzheimer Disease Cooperative Study, University of California, San Diego, CA, USA.
Sylvie BellevilleDeparment of Psychology, Université de Montréal, Montréal, Québec, Canada.
Howard ChertkowRotman Research Institute, Baycrest Health Sciences, Toronto, ON, Canada.
Haakon B NygaardDivision of Neurology, Charles E. Fipke Integrated Neuroimaging Suite, University of British Columbia, Vancouver, BC, Canada.
Surim SonDepartment of Epidemiology and Biostatistics, The University of Western Ontario, London, ON, Canada.
Mark SpeechleyDepartment of Epidemiology and Biostatistics, The University of Western Ontario, London, ON, Canada.
Western University · CABaycrest Hospital · CALawson Health Research Institute · CAUniversité de Montréal · CAUniversity of British Columbia · CAUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultidomain trials to prevent dementia by simultaneously targeting multiple risk factors with non-pharmacological lifestyle interventions show promise. Designing trials to evaluate the efficacy of individual interventions and their combinations is methodologically challenging. Determining the efficacy is, nevertheless, important to individuals, payers, and for resource allocations to support intervention implementation. MAIN BODY: The central rationale for seminal trials improving cardiovascular health or reducing falls risk in older adults is that multifactorial conditions may be amenable to improvement by simultaneously targeting multiple modifiable risk factors. Similar reasoning underlies lifestyle interventions to reduce dementia risk using combinations of physical exercise, cognitive training, diet, amelioration of vascular-metabolic risk factors, and improving sleep quality. Randomizing individuals with at least two modifiable risk factors to "standardly tailored" interventions to mitigate their risk factors, versus a comparator arm, will yield an unbiased estimate of the cumulative average effect of modifying more versus fewer risk factors. The between-group difference in the cognitive primary outcome will reflect both the main effects of the mitigated risk factors, as well as their synergistic effects. However, given the positive trial results, there are inherent challenges in quantifying post hoc which components, or combination of components, were responsible for improvements in cognition. Here, we elaborate on these methodological challenges and important considerations in using a standardly tailored design with two arms (one consisting of multidomain interventions tailored to participants' risk profiles and another consisting of active control conditions). We compare this approach to fully factorial designs and highlight the disadvantages and advantages of each. We discuss partial solutions, including analytical strategies such as risk reduction scores that measure reductions in the number or severity of risk factors in each study arm. Positive results can support the causal inference that between-group differences in the primary cognitive outcome were due to risk factor modification.

conclusionStandardly tailored designs are pragmatic and feasible evaluations of multidomain interventions to reduce dementia risk. We propose sensitivity and exploratory analyses of between-group reductions in the severity of risk factors, as a methodology to bolster causal inferences that between-group differences in the primary cognitive outcome are due to the risk factors modified.

Indexed as

DementiaLife StyleAgedCognitionHumansRisk FactorsRisk Reduction BehaviorCombined interventionsDementiaMultidomain trialsMultifactorial interventions

Identifiers

PMID35820915
PMCPMC9275261
OpenAlexW4285042905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.